Cover Image
市場調查報告書

骨質疏鬆症:開發中產品分析

Osteoporosis - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 232788
出版日期 內容資訊 英文 263 Pages
訂單完成後即時交付
價格
Back to Top
骨質疏鬆症:開發中產品分析 Osteoporosis - Pipeline Review, H2 2017
出版日期: 2017年10月31日 內容資訊: 英文 263 Pages
簡介

骨質疏鬆症是由於骨量減少造成骨頭強度減弱而容易骨折的疾病。高齡、性別、體重輕、性荷爾蒙的不足或閉經、抽煙、特定藥劑都是致病風險。症狀是脊椎的破損和壓迫骨折的腰痛,身高變矮、姿勢前屈、容易骨折等,預防或治療方法有攝取鈣,維他命D、透過運動、治療藥等治療。

本報告提供骨質疏鬆症的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

骨質疏鬆症 - 概要

骨質疏鬆症 - 治療藥的開發

  • 開發平台概要
  • 各企業的開發平台趨勢
  • 各大學·研究機關的開發平台趨勢
  • 企業開發中的產品
  • 大學·研究機關開發中的產品

骨質疏鬆症 - 治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

骨質疏鬆症的開發治療藥的企業

  • Addex Therapeutics Ltd
  • Alize Pharma SAS
  • Alvogen Korea Co Ltd
  • Amgen Inc
  • Amura Holdings Ltd
  • BiologicsMD Inc
  • Bone Biologics Corp
  • Bristol-Myers Squibb Company
  • Cellmid Ltd
  • ChoDang Pharm Co Ltd
  • Chugai Pharmaceutical Co Ltd
  • Corium International Inc
  • Critical Pharmaceuticals Ltd
  • 第一三共
  • ElexoPharm GmbH
  • EndoCeutics Inc
  • Entera Bio Ltd
  • Enteris BioPharma Inc
  • Enzo Biochem Inc
  • F. Hoffmann-La Roche Ltd
  • Gador SA
  • GL Pharm Tech Corp
  • Glide Pharmaceutical Technologies Ltd
  • Hanmi Pharmaceuticals Co Ltd
  • Haoma Medica Ltd
  • Immunovo BV
  • Immunwork Inc
  • Intas Pharmaceuticals Ltd
  • Ipsen SA
  • Kaken Pharmaceutical Co Ltd
  • Lead Discovery Center GmbH
  • Ligand Pharmaceuticals Inc
  • Lotus Pharmaceutical Co Ltd
  • Lupin Ltd
  • Merck & Co Inc
  • Mereo Biopharma Group Plc
  • NIBEC
  • Omeros Corp
  • Oncobiologics Inc
  • Osteologix Holdings Plc
  • Paras Biopharmaceuticals Finland Oy
  • Pfenex Inc
  • PhytoHealth Corp
  • R Pharm
  • Ribomic Inc
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
  • Shin Poong PharmCo Ltd
  • Sinil Pharmaceutical Co Ltd
  • Stelis Biopharma Pvt Ltd
  • Sumitomo Dainippon Pharma Co Ltd
  • Terpenoid Therapeutics Inc
  • TSH Biopharm Corporation Ltd
  • Uni-Bio Science Group Ltd
  • Viking Therapeutics Inc
  • Wroclawskie Centrum Badan EIT+ Sp z oo
  • Yooyoung Pharm Co Ltd
  • Zydus Cadila Healthcare Ltd

藥物簡介

骨質疏鬆症 - 暫停中的計劃

骨質疏鬆症 - 開發中止的產品

骨質疏鬆症 - 產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9819IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoporosis - Pipeline Review, H2 2017, provides an overview of the Osteoporosis (Metabolic Disorders) pipeline landscape.

Osteoporosis, or thinning bones, makes bones weak and more likely to break. Risk factors for osteoporosis include aging, being female, low body weight, low sex hormones or menopause, smoking, and some medications. Signs and symptoms include back pain, caused by a fractured or collapsed vertebra, loss of height over time, a stooped posture, a bone fracture that occurs much more easily than expected. Prevention and treatment include calcium and vitamin D, exercise, and osteoporosis medications.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteoporosis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteoporosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteoporosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 7, 5, 5, 13, 1, 55 and 13 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 11 and 14 molecules, respectively.

Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoporosis (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Osteoporosis (Metabolic Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Osteoporosis (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Osteoporosis - Overview
  • Osteoporosis - Therapeutics Development
  • Osteoporosis - Therapeutics Assessment
  • Osteoporosis - Companies Involved in Therapeutics Development
  • Osteoporosis - Drug Profiles
  • Osteoporosis - Dormant Projects
  • Osteoporosis - Discontinued Products
  • Osteoporosis - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Osteoporosis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..4), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..5), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Osteoporosis - Pipeline by Abreos Biosciences Inc, H2 2017
  • Osteoporosis - Pipeline by Alize Pharma SAS, H2 2017
  • Osteoporosis - Pipeline by Alvogen Korea Co Ltd, H2 2017
  • Osteoporosis - Pipeline by Amgen Inc, H2 2017
  • Osteoporosis - Pipeline by Amura Holdings Ltd, H2 2017
  • Osteoporosis - Pipeline by BiologicsMD Inc, H2 2017
  • Osteoporosis - Pipeline by Bone Biologics Corp, H2 2017
  • Osteoporosis - Pipeline by Bristol-Myers Squibb Co, H2 2017
  • Osteoporosis - Pipeline by Cadila Healthcare Ltd, H2 2017
  • Osteoporosis - Pipeline by Cellmid Ltd, H2 2017
  • Osteoporosis - Pipeline by ChoDang Pharm Co Ltd, H2 2017
  • Osteoporosis - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2017
  • Osteoporosis - Pipeline by Corium International Inc, H2 2017
  • Osteoporosis - Pipeline by Critical Pharmaceuticals Ltd, H2 2017
  • Osteoporosis - Pipeline by Daiichi Sankyo Co Ltd, H2 2017
  • Osteoporosis - Pipeline by ElexoPharm GmbH, H2 2017
  • Osteoporosis - Pipeline by EndoCeutics Inc, H2 2017
  • Osteoporosis - Pipeline by Entera Bio Ltd, H2 2017
  • Osteoporosis - Pipeline by Enteris BioPharma Inc, H2 2017
  • Osteoporosis - Pipeline by Enzene Biosciences Ltd, H2 2017
  • Osteoporosis - Pipeline by Enzo Biochem Inc, H2 2017
  • Osteoporosis - Pipeline by Evgen Pharma Plc, H2 2017
  • Osteoporosis - Pipeline by Gador SA, H2 2017
  • Osteoporosis - Pipeline by GL Pharm Tech Corp, H2 2017
  • Osteoporosis - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017
  • Osteoporosis - Pipeline by Haoma Medica Ltd, H2 2017
  • Osteoporosis - Pipeline by Immunovo BV, H2 2017
  • Osteoporosis - Pipeline by Immunwork Inc, H2 2017
  • Osteoporosis - Pipeline by Intas Pharmaceuticals Ltd, H2 2017
  • Osteoporosis - Pipeline by Ipsen SA, H2 2017
  • Osteoporosis - Pipeline by Kaken Pharmaceutical Co Ltd, H2 2017
  • Osteoporosis - Pipeline by Lead Discovery Center GmbH, H2 2017
  • Osteoporosis - Pipeline by Lotus Pharmaceutical Co Ltd, H2 2017
  • Osteoporosis - Pipeline by Lupin Ltd, H2 2017
  • Osteoporosis - Pipeline by Luye Pharma Group Ltd, H2 2017
  • Osteoporosis - Pipeline by mAbxience SA, H2 2017
  • Osteoporosis - Pipeline by Merck & Co Inc, H2 2017
  • Osteoporosis - Pipeline by Mereo Biopharma Group Plc, H2 2017
  • Osteoporosis - Pipeline by NIBEC, H2 2017
  • Osteoporosis - Pipeline by Omeros Corp, H2 2017
  • Osteoporosis - Pipeline by Oncobiologics Inc, H2 2017
  • Osteoporosis - Pipeline by Paras Biopharmaceuticals Finland Oy, H2 2017
  • Osteoporosis - Pipeline by Pfenex Inc, H2 2017
  • Osteoporosis - Pipeline by PhytoHealth Corp, H2 2017
  • Osteoporosis - Pipeline by R Pharm, H2 2017
  • Osteoporosis - Pipeline by Ribomic Inc, H2 2017
  • Osteoporosis - Pipeline by Sermonix Pharmaceuticals LLC, H2 2017
  • Osteoporosis - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H2 2017
  • Osteoporosis - Pipeline by Shin Poong PharmCo Ltd, H2 2017
  • Osteoporosis - Pipeline by Sinil Pharmaceutical Co Ltd, H2 2017
  • Osteoporosis - Pipeline by Stelis Biopharma Pvt Ltd, H2 2017
  • Osteoporosis - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017
  • Osteoporosis - Pipeline by Terpenoid Therapeutics Inc, H2 2017
  • Osteoporosis - Pipeline by TSH Biopharm Corporation Ltd, H2 2017
  • Osteoporosis - Pipeline by Uni-Bio Science Group Ltd, H2 2017
  • Osteoporosis - Pipeline by Viking Therapeutics Inc, H2 2017
  • Osteoporosis - Pipeline by Wroclawskie Centrum Badan EIT+ Sp z oo, H2 2017
  • Osteoporosis - Pipeline by Yooyoung Pharm Co Ltd, H2 2017
  • Osteoporosis - Dormant Projects, H2 2017
  • Osteoporosis - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Osteoporosis - Dormant Projects, H2 2017 (Contd..2), H2 2017
  • Osteoporosis - Dormant Projects, H2 2017 (Contd..3), H2 2017
  • Osteoporosis - Dormant Projects, H2 2017 (Contd..4), H2 2017
  • Osteoporosis - Dormant Projects, H2 2017 (Contd..5), H2 2017
  • Osteoporosis - Dormant Projects, H2 2017 (Contd..6), H2 2017
  • Osteoporosis - Dormant Projects, H2 2017 (Contd..7), H2 2017
  • Osteoporosis - Discontinued Products, H2 2017
  • Osteoporosis - Discontinued Products, H2 2017 (Contd..1), H2 2017

List of Figures

  • Number of Products under Development for Osteoporosis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Top 10 Molecule Types, H2 2017
  • Number of Products by Stage and Top 10 Molecule Types, H2 2017
Back to Top